Is “Geriatric” Assessment Just for Older Patients? by Aleixo, G.F.P. et al.
Is “Geriatric” Assessment Just for Older Patients?
GABRIEL F.P. ALEIXO,a SEUL KI CHOI,b ALYSSA J. TAN,b KIRSTEN A. NYROP,a ALYSON M. DEAL,a WILLIAM A. WOOD,a TREVOR A. JOLLY,a
HYMAN B. MUSSa
aDepartment of Hematology-Oncology and bGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel
Hill, North Carolina, USA
Disclosures of potential conflicts of interest may be found at the end of this article.
ABSTRACT
Geriatric assessment (GA) is used in oncology to identify
deficits in older patients with cancer that may affect treat-
ment choice. We examine GA in 550 patients with early
breast cancer, including both younger (<65 years) and
older women (aged 65 years or older), to assess the poten-
tial value of this tool in younger, presumed “healthier”
patients. Although older women have more GA-identified
deficits overall, younger patients are more anxious. Sub-
optimal physical function was problematic across the age
spectrum. GA domains can identify major deficits in youn-
ger patients beyond those likely to be uncovered in rou-
tine investigation. The Oncologist 2020;25:355–358
INTRODUCTION
Geriatric assessment (GA) is recognized as an important
tool in oncology practice to identify deficits in older
patients with cancer that can help estimate life expec-
tancy [1], predict treatment-related toxicity [2, 3], and
assess the risk of hospitalization. In addition, the GA can
identify problems such as falls, polypharmacy, and inad-
equate social support, for which evidence-based inter-
ventions may improve outcomes. A brief GA can be
readily administered in clinical practice [4, 5] and
includes all major domains relevant to identifying defi-
cits of importance in treatment decisions of older
patients with cancer. The mental status exam and Timed
Up and Go (TUG) test are administered by the clinician
or research personnel, whereas the remainder of the
brief GA relies on patient self-report to identify key defi-
cits. This reflects much of current health outcomes
research, which focuses on patient-reported outcomes
[6]. Our prior research has shown that in adults age
65 years and older who have a Karnofsky Performance
Status (KPS) score of 80 or higher, the brief GA can iden-
tify major deficits that may affect cancer treatment tol-
erance and outcomes [7].
The cutoff age (65–70) used to define “geriatric” is arbi-
trary, based on factors such as Medicare and social security
eligibility. In practice, there is no age at which a patient is
considered “older”; therefore, in theory, “geriatric” deficits
may have implications for younger patients as well. In this
study, we explore the frequency of GA deficits identified in
younger patients and examine the value of this tool in a
sample that includes both younger (<65) and older (≥65)
women with early breast cancer.
MATERIALS AND METHODS
The sample consists of women with early breast cancer (stage
I–III) enrolled in the Carolina Senior Registry (NCT01137825);
some of the women were enrolled through an exercise inter-
vention trial (NCT011789983, NCT02167932, NCT02328313,
NCT037611706) for home-based walking during chemother-
apy. In the intervention trials, all study participants completed
the brief GA prior to chemotherapy and exercise intervention.
Measures included in the brief GA have been described previ-
ously in detail [4, 7]. Table 1 includes cut points for the identi-
fication of significant deficits.
The data were analyzed in three age cohorts: age < 50,
age 50–64, and age 65 and older. Percentages and means
are compared between groups using chi-squared tests for
categorical variables and analysis of variance for continuous
variables.
RESULTS
Table 1 summarizes our findings. Among the 550 women,
455 (82%) were age 65 or older, 51 (9%) age 50–64, and 44
(8%) less than age 50. Women age 65 plus were more likely
to be white (p = .004), have a level of education of high
school or less (p = .006), and have lower KPS <80 (p = .003),
slower gait speed (TUG >14 seconds; p = .003), more com-
orbidities (p < .0001), poorer hearing (p = .0005), higher rates
of unintentional weight loss (p = .006), worse physical func-
tion (p < .0001), and more instrumental activities of daily liv-
ing (IADL) deficits (p = .01). Women under age 50 had
greater anxiety (Mental Health Index [MHI]; p = .04). There
were no significant differences among the age cohorts for
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(n = 44; 8%)
Age
50–64 years
(n = 51; 9%)
Age ≥
65 years
(n = 455; 83%) p value
Age, mean (SD) [range], years 69.5 (11.6) [24–93] 41.5 (5.9) [24–49] 56.1 (4.2) [50–64] 73.7 (6.7) [65–93]
Race, n (%) .0043
Not white 106 (19) 14 (32) 16 (31) 76 (17)
White 440 (81) 30 (68) 35 (69) 375 (83)
Education, n (%) .0058
High school or less 247 (49) 16 (38) 15 (31) 216 (52)
More than high school 258 (51) 26 (62) 34 (69) 198 (48)
Married .8744
Yes 294 (58) 23 (55) 28 (57) 243 (59)
Body mass index, mean (SD) [range] 28 (6.2) [15–65] 28.2 (6.4) [19–44] 29.1 (5.7) [20–42] 27.9 (6.2) [15–64] .3972
Karnofsky Performance Status <80,
n (%)
68 (13) 0 (0) 2 (4) 66 (15) .0027
Timed Up and Go test—no more than
14 seconds, n (%)
152 (28) 7 (16) 6 (12) 139 (31) .0026
Patient Karnofsky Performance Status
<80, n (%)
79 (16) 6 (15) 5 (11) 68 (17) .5581
Falls in past 6 months .3473
None 388 (79) 33 (85) 41 (85) 314 (78)
One or more 101 (21) 6 (15) 7 (15) 88 (22)
Comorbidities (continuous), mean (SD)
[range]
2 (1.6) [0–9] 0.4 (0.8) [0–3] 1.4 (1.6) [0–9] 2.2 (1.5) [0–9] <.0001
Comorbidities, n (%)
Arthritis or rheumatism 225 (46) 3 (8) 13 (27) 209 (52) .0001
Glaucoma 28 (6) 0 (0) 3 (6) 25 (6) .2810
Emphysema or chronic bronchitis 33 (7) 0 (0) 1 (2) 32 (8) .0687
High blood pressure 240 (49) 3 (8) 21 (44) 216 (54) .0001
Heart disease 65 (13) 0 (0) 2 (4) 63 (16) .0034
Peripheral vascular disease 76 (16) 2 (5) 7 (15) 67 (17) .1669
Diabetes 77 (16) 1 (3) 6 (12) 70 (17) .0511
Stomach or intestinal problems 71 (15) 2 (5) 4 (8) 65 (16) .0818
Osteoporosis 58 (12) 0 (0) 2 (4) 56 (14) .0085
Chronic liver or kidney disease 12 (2) 1 (3) 1 (2) 10 (2) .9811
Stroke 22 (4) 0 (0) 2 (4) 20 (5) .3671
Depression 88 (18) 5 (13) 9 (195) 74 (18) .7039
Poor eyesight/totally blind, n (%) 9 (2) 0 (0) 1 (2) 8 (2) .9441
Poor hearing, n (%) 20 (4) 0 (0) 0 (0) 20 (5) .0005
Unintentional weight loss, n (%) 148 (28) 8 (21) 5 (10) 135 (31) 0063
Lower Physical Function Score < 20,
n (%)
323 (79) 24 (62) 29 (62) 270 (84) <.0001
Poor Instrumental Activities of Daily
Living—score < 14, n (%)
142 (29) 5 (14) 8 (17) 129 (32) .0098
Lower Social Activity Limit Score
(range 0–100)—score < 50, n (%)
68 (16) 7 (18) 12 (26) 49 (15) .1690
Lower Social Support-Emotional Score
(range 0–100)—score < 50, n (%)
18 (4) 1 (3) 5 (11) 12 (4) .0823
Lower Social
Support-Tangible/Instrumental Score
(range 0–100)—score < 50, n (%)
25 (6) 1 (3) 6 (13) 18 (5) .0898
Mental Health Index-Depressed (range
0–43)—depressed (score ≥ 12), n (%)
117 (25) 13 (35) 12 (26) 92 (24) .3640
Mental Health Index-Anxious (range
0–20)—anxious (score ≥ 6), n (%)
172 (36) 21 (55) 17 (36) 142 (35) .0402
patient-reported KPS, falls, depression, eyesight, social activ-
ity limitations, and social support—tangible (instrumental) or
emotional. Figure 1 presents individual components of the
physical function scale, with significant differences found in 8
of 10 components.
had the highest proportion defined as anxious (55%) or
depressed (35%), reflecting the emotional toll of a cancer
diagnosis.
The brief GA takes on average 10 minutes for the profes-
sionally assessed items and 20 minutes for patient-reported
items [7], and there is growing interest in making the brief
GA an integral component of cancer care in older patients
[5], especially for chemotherapy decisions [2]. Our findings
suggest that a brief assessment may also be valuable in treat-
ment decisions for patients with breast cancer under age 65.
Our findings pertaining to functional capacity among patients
<50 and 50–64 years are alarming; 62% of both age groups
had suboptimal physical function scores, and 14% and 17%
had IADL limitations, respectively. This is noteworthy as this
age group included patients who were scheduled to receive
adjuvant chemotherapy. One would expect to find even
higher rates of deficits in both younger and older patients
with metastatic disease receiving palliative chemotherapy.
Our study shows that domains evaluated in the GA are likely
to identify major deficits in younger patients beyond those
uncovered in the routine history and physical examination.
Clinicians may wish to select a limited set of GA measures to
incorporate into their routine medical evaluations, to reduce
the amount of time that the full GA entails. The GA is likely
to be helpful in evaluating all patients with cancer, and revis-
ing it to add assessment such as financial toxicity should be
the subject for further research. Our data indicate that GA is
not just for older patients.
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Vigorous activity (running, lifting heavy objects, strenuous
sports)  (p < .0001)
Moderate activity (vacuuming, bowling, playing golf)
(p = .053)
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Figure 1. Physical function deficits (%).
DISCUSSION
Our findings confirm the high proportion of older women 
with GA-identified deficits. However, we also found that 
younger patients had substantial deficits detected by the 
brief GA. We note that women of all ages who participated
in the intervention trials had been deemed “fit” for the che-
motherapy by their oncology provider. Figure 1 shows that 
23% of women age < 50 and 33% of women age 50–64 had 
difficulties with vigorous activity, such as running and lifting 
heavy objects. Being able to maintain levels of activity and 
exercise are important to quality of life and living indepen-
dently in the community [8]. Furthermore, 15% of patients 
<65 years experienced a fall in the past 6 months, and 16%of 
women <50 years and 12% of women age 50–65 years had 
TUG scores >14 seconds. Slower gait speeds and recur-rent 
falls are considered indicators of poor outcomes in older 
patients [9] but would be a concern among younger patients 
as well.
Participants age 50–64 are generally thought to be 
“healthy”; however, their mean number of comorbidities was 
similar to that of women age 65 years and older (1.6 vs. 
2.1). The age 50–64 cohort also had the highest proportion 
with social activity limitations (26%) and lowest social 
support (11% emotional, 13% tangible/instrumental). The 
MHI-13 is an accurate method for detecting anxiety and 
depression in patients with cancer [10]. In our study, women 
age < 50 years
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Editor’s Note:
See the related article, “When It Comes to Geriatric Assessment, Rome Was Not Built in One Day” by Armin Shahrokni,
Stuart Lichtman, and Beatriz Korc-Grodzicki on page 279 of this issue.
